Harmony Biosciences Holdings, Inc.

Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) resulting from allegations that Harmony Biosciences may have issued materially misleading business information to the investing public.

If you purchased Harmony Biosciences securities and would like to join the prospective action, please click “Join This Class Action.”

If you purchased Harmony Biosciences securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Details of investigation:

On March 28, 2023, before the market opened, market analyst Scorpion Capital published a report on Harmony Biosciences. The report alleged, among other things, that Harmony’s drug, Wakix (pitolisant), is unsafe and causes heart-related issues (including sudden cardiac death) to occur in patients who are otherwise healthy. The report further alleged that, to obtain approval for Wakix from the United States Food & Drug Administration (“FDA”), Harmony Biosciences obtained approval in foreign nations with allegedly lax drug safety controls, such as Russia, before tricking the FDA into approving the drug based on the prior approvals. The report also alleged that the company engaged in kickback schemes to pay physicians to use its drugs, has a sham patent portfolio, and engages in false advertising.

On this news, Harmony Bioscience’s stock price fell as much as $11.34 per share, or 27.33%, in intraday trading.

Follow us on:
Company Name: Harmony Biosciences Holdings, Inc.
Stock Symbol: HRMY
Class Period: N/A
Court: N/A

Why Rosen Law

The Rosen Law Firm has been ranked among the top 4 law firms each year since 2013 for the number of successful securities class actions on behalf of investors. In 2019 alone, our firm recovered $438 million for investors.

Investors should carefully identify and select experienced counsel with a track record of success leading securities class actions. Often other firms issue press releases about class actions yet do not have comparable experience or resources.

Institutional Shareholders Services ranked the Rosen Law Firm # 1 for the number of securities class action recoveries in 2017.

The Rosen Law Firm represents investors throughout the globe. Our mission is to prosecute securities fraud class actions and protect shareholders’ rights.

Scroll to Top